NASDAQ · CRVO
CervoMed Inc.
$1.75-$0.46 (-20.81%)
CervoMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.5% below the high.
Loading market information…
NASDAQ · TSBX · USD
Stock price, earnings
Quote as of Aug 11, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Turnstone Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.3% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Turnstone Biologics Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Turnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers. Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 |
|---|
| Nov 9, 2023 |
| -$1.00-49.25% vs estimate |
| $0.00 |
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.75-$0.46 (-20.81%)
CervoMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.5% below the high.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$0.39+$0.03 (+8.48%)
Apexigen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$1.35+$0.09 (+7.14%)
Channel Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.51% below the high.
$0.14$0.00 (0.0%)
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
$0.57-$0.26 (-30.77%)
Kineta, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.34% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
